Several studies have shown that MGMT deficiency resulting from MGMT promoter methylation may confer increased sensitivity to alkylating agents, yet some glioma patients with MGMT promoter methylation still exhibit resistance to these drugs [25, 48]. Here, MGMT is linked to central nervous system cancer.